$ACT

Stolove Evan sold $992K of ACT

Stolove Evan (EVP, Gen. Counsel & Secretary) sold 20,024 shares of Enact Holdings, Inc. (ACT) at $49.52 ($0.99M total) on 2026-08-17.

Original reporting
SEC EDGAR · Stolove Evan
Published Aug 19, 2026, 8:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ACT
Bearish
medium confidence
Mentioned
$ACT
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACTBearishLow
01

Why it matters

The insider sale may lead to short-term price pressure, but the overall impact is limited given the modest transaction size.

02

Market read

Primary insider sale filing; modest size but senior insider involvement gives some relevance.

03

What to watch

No 10b5-1 plan; sale may be discretionary.

Relevance 5/10Novelty 5/10Timing: filed today

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources of new information.

Company-level read

Ticker impact

$ACTBearishMedium confidence
Context

EVP Evan Stolove sold 20,024 shares of Enact Holdings for $991,668, reducing his stake to 32,003 shares.

Expected impact

Possible modest dip in ACT price over the next few days.

Evidence & confidence

Sale size is under $1M but involves a senior officer; market may react negatively.

Market effects

Minimal impact on the broader sector; only reflects company-specific insider activity.

None

None

Counterpoint

The sale could be routine liquidity need, not a negative signal.

Key entities

  • Enact Holdings, Inc.

    Issuer of the stock (ticker ACT).

  • Evan Stolove

    Executive Vice President, General Counsel & Secretary.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ACTMedAI 8/10

Enact (ACT) Q2 2026 Earnings Call Transcript

Enact (ACT) reported Q2 2026 adjusted operating income of $177 million, or $1.26 per diluted share, up from $174 million, or $1.15, in Q2 2025. New insurance written rose 15% to $15 billion. FY2026 capital return guidance was raised to $550 million to $600 million. Management cited $274 billion insurance in force and 161% PMIERs sufficiency.